Journal
CLINICAL NEUROPHARMACOLOGY
Volume 36, Issue 3, Pages 98-99Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WNF.0b013e3182908330
Keywords
aripiprazole; antipsychotics; cannabis/adverse effects; psychoses; substance-induced; schizophrenia; therapeutics
Categories
Ask authors/readers for more resources
Cannabis-induced psychotic symptoms (CIPSs) have both similarities and differences with positive symptoms of schizophrenia, and it remains unclear whether CIPSs result from dopaminergic mechanisms and can be treated with antipsychotics. We report the case of a 22-year-old male patient with ultrahigh risk criteria for psychosis, who reported cannabis addiction and recurrent CIPSs. Aripiprazole 10 mg/d could totally and durably suppress CIPSs in the patient, but had no effect on the smoking level. Treating CIPSs in ultrahigh risk individuals who cannot stop or refuse stopping cannabis might fit a harm-reduction strategy by preventing transition into psychosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available